NYSE$ACH

Accendra Health Inc · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

Reported solid growth in both segments and reduced debt through operating cash flow.

Owens & Minor reported a 4% increase in consolidated revenue, driven by growth in both the Products & Healthcare Services and Patient Direct segments. The company generated $116 million in operating cash flow, which enabled a $71 million debt reduction. However, the company reported a net loss of $(32) million, or $(0.42) per share.

  • Consolidated revenue increased by 4% year-over-year to $2.7 billion.
  • Net loss was $(32) million, or $(0.42) per share.
  • Adjusted EBITDA grew by 12% year-over-year to $127 million.
  • Adjusted earnings per share doubled year-over-year from $0.18 to $0.36.

Headline financials

Total Revenue

$2.67B

Previous: $2.56B+4.2%
EPS

-$0.42

Previous: $0.18-333.3%
Adjusted Operating Income

$52.8M

No prior period
Adjusted EBITDA

$91.1M

Previous: $113M-19.2%
Patient Service Equipment CapEx

$24.9M

No prior period
Capital Expenditures

-$90.4M

Previous: -$92.8M+2.6%
Free Cash Flow

-$122M

Previous: -$121M-1.1%
Net Income

-$31.9M

Previous: -$28.2M-13.0%
Operating Income

$20.3M

Previous: $10.8M+87.3%
Gross Profit

$544M

Previous: $519M+4.8%
Cash & Equivalents

$244M

Previous: $286M-14.9%
Total Assets

$5.3B

Previous: $5.29B+0.3%
Stock-Based Comp

$6.74M

Previous: $5.21M+29.2%

Revenue & EPS history

Owens & Minor · Revenue · Quarterly

$2.67B

Q2 2024+4.2%vs Q2 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Forward guidance

The company reaffirmed its financial guidance for 2024.

Tailwinds

  • Revenue for 2024 to be in a range of $10.5 billion to $10.9 billion
  • Adjusted EBITDA for 2024 to be in a range of $550 million to $590 million
  • Adjusted EPS for 2024 to be in a range of $1.40 to $1.70
  • Gross margin rate of 21.0% to 21.5%
  • Adjusted effective tax rate of 27.5% to 28.5%

Headwinds

  • Guidance contains assumptions, including current expectations regarding the impact of general economic conditions, including inflation
  • Guidance includes the continuation of pressure on pricing and demand in our Products & Healthcare Services segment
  • Interest expense of $141 to $146 million
  • Diluted weighted average shares of ~78.5 million
  • Capital expenditures of $220 to $240 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

+0.5%

Avg return

Earnings day

-0.2%

Avg return

5 days after

+2.3%

Avg return

30 days after

47%

32 / 68 earnings

Positive

+58.9%

Q2 2019

Best reaction

-37.6%

Q3 2018

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+8.7%-18.7%-23.7%
Q4 2025+5.7%+4.8%-21.0%
Q3 2025-4.8%-33.1%-47.9%
Q1 2025-9.6%-6.8%+3.2%
Q4 2024+39.0%+41.4%+24.5%
Q3 2024-11.7%-3.4%+10.3%
Q2 2024-9.4%-9.7%-5.4%
Q1 2024-21.6%-26.1%-28.9%
Q4 2023+2.7%+12.6%+23.1%
Q3 2023+25.0%+19.1%+39.5%
Q2 2023+2.5%+8.4%-6.8%
Q1 2023+31.2%+35.7%+57.4%
Q4 2022-21.3%-13.8%-28.1%
Q3 2022+3.9%+9.2%+19.8%
Q2 2022-10.8%-6.7%-25.8%
Q1 2022+10.3%+4.7%-5.2%
Q4 2021+13.3%+21.0%+21.6%
Q3 2021+23.8%+18.3%+9.5%
Q2 2021-16.8%-16.8%-16.7%
Q1 2021-4.0%-4.7%+19.8%
Q4 2020+27.8%+34.3%+51.3%
Q3 2020+1.3%-2.5%+0.2%
Q2 2020-16.2%-25.0%-2.9%
Q1 2020-6.3%-2.9%+5.6%
Q4 2019-12.0%-30.0%+0.6%
Q3 2019+8.1%+5.9%+16.9%
Q2 2019+58.9%+69.1%+148.1%
Q1 2019+7.4%+7.4%-27.1%
Q4 2018-16.6%-19.1%-45.1%
Q3 2018-37.6%-33.9%-46.3%
Q2 2018-21.7%-24.4%-5.7%
Q1 2018+6.8%+9.4%+8.2%
Q4 2017+4.4%+7.6%+9.3%
Q3 2017-24.0%-21.2%-23.7%
Q2 2017-5.9%-11.9%-13.3%
Q1 2017-4.8%-5.4%-6.3%
Q4 2016-2.6%-2.6%-2.3%
Q3 2016+1.0%+0.6%+5.4%
Q2 2016-0.1%-0.1%-2.3%
Q1 2016-2.2%
Q4 2015+7.9%
Q3 2015+1.1%
Q2 2015+5.1%
Q1 2015+3.8%
Q4 2014-3.3%
Q3 2014-2.1%
Q2 2014-2.7%
Q1 2014-2.4%
Q4 2013+3.8%
Q3 2013-1.5%
Q2 2013-3.5%
Q1 2013+6.9%
Q4 2012-1.1%
Q3 2012-1.0%
Q2 2012-6.0%
Q1 2012-2.5%
Q4 2011-0.1%
Q3 2011-1.5%
Q2 2011+0.3%
Q1 2010-0.2%
Q1 2011+2.1%
Q4 2008+2.5%
Q4 2010+2.5%
Q3 2009-1.4%
Q3 2010-1.4%
Q2 2010+2.4%
Q2 2009+2.4%
Q4 2009+2.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro